AzTrials
AzTrials

SCHIZOPHRENIA 1 (Disorder)NCT07190352

Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in Schizophrenia

A study testing iTBS to the DMN and cTBS to the DMN in people with SCHIZOPHRENIA 1 (Disorder) and Nicotine Use, run by Beth Israel Deaconess Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary aims of this study are to investigate the behavioral effects of applying targeted transcranial magnetic stimulation (TMS) to a node of the brain network subserving attention in schizophrenia and schizoaffective disorder and to correlate these effects to changes in brain network connectivity. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
SCHIZOPHRENIA 1 (Disorder), Nicotine Use
What is being tested?
iTBS to the DMN and cTBS to the DMN
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
15 participants
Where
1 siteUnited States
Study dates
4 Oct 2021to 3 Oct 2022
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age between 18-65 years
  • At pre-visit screening (see attached phone screening questionnaire): Subjects must report that they have been given a diagnosis of schizophrenia or schizoaffective disorder by a mental health professional
  • Current smoker (expired air CO of 5ppm or higher)
  • Must be able to read, speak and understand English
  • Must be judged by study staff to be capable of completing the study procedures
  • Diagnosis of either schizophrenia or schizoaffective disorder according to DSM-V criteria and confirmed by SCID[26]
  • Participants will be in stable outpatient treatment with no recent (within the past 30 days) hospitalizations or changes in their medication regimens.

Who cannot join

  • DSM-V intellectual disability
  • Substance use disorder within the past three months
  • Any history of a progressive or genetic neurologic disorder (e.g. Parkinson's disease, multiple sclerosis, tuberous sclerosis, Alzheimer's Disease) or acquired neurological disease (e.g. stroke, traumatic brain injury, tumor), including intracranial lesions
  • History of head trauma resulting in any loss of consciousness (>15 minutes) or neurological sequelae
  • Current history of poorly controlled headaches including chronic medication for migraine prevention
  • History of fainting spells of unknown or undetermined etiology that might constitute seizures
Show all 14Show fewer
  • History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist
  • Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
  • Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)
  • Any devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible covering MD
  • All female participants of child-bearing age will be required to have a pregnancy test; any participant who is pregnant will not be enrolled in the study
  • Medications will be reviewed by the responsible covering physician and a decision about inclusion will be made based on the participant's past medical history, drug dose, history of recent medication changes or duration of treatment, and use of CNS active drugs. The published TMS guidelines review of medications to be considered with rTMS will be taken into consideration given their described effects on cortical excitability measures.
  • Any changes in medications or hospitalizations within the past 30 days.
  • Subjects who, in the investigator's opinion, might not be suitable for the study or would be unable to tolerate the study visit.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

Other trials in United States

About this study

The primary aims of this study are to investigate the behavioral effects of applying targeted transcranial magnetic stimulation (TMS) to a node of the brain network subserving attention in schizophrenia and schizoaffective disorder and to correlate these effects to changes in brain network connectivity. Assumptions: -Cerebral activity can be investigated through the correlated activity of cortical nodes that constitute functional brain networks -Behavior can be correlated to the strength of correlated activity between and within nodes of these cortical networks -TMS to targeted nodes leads to changes in patterns of activity in these cortical networks Hypothesis: TMS to a node of the attention network in schizophrenia or schizoaffective disorder will influence network connectivity leading to measurable and predictable effects on attention.

Read the detailed description

The primary aims of this study are to investigate the behavioral effects of applying targeted transcranial magnetic stimulation (TMS) to a node of the brain network subserving attention in schizophrenia and schizoaffective disorder and to correlate these effects to changes in brain network connectivity.

Assumptions:

  • Cerebral activity can be investigated through the correlated activity of cortical nodes that constitute functional brain networks
  • Behavior can be correlated to the strength of correlated activity between and within nodes of these cortical networks
  • TMS to targeted nodes leads to changes in patterns of activity in these cortical networks

Hypothesis:

TMS to a node of the attention network in schizophrenia or schizoaffective disorder will influence network connectivity leading to measurable and predictable effects on attention.

Aim 1: Test if network connectivity reflects cognitive performance using an independent sample of individuals with schizophrenia or schizoaffective disorder (n=50). Hypothesis 1A: Network connectivity will predict attentional performance in schizophrenia and schizoaffective disorder. Hypothesis 1B: The magnitude of attentional performance improvement after TMS is also explained by change in network connectivity in schizophrenia and schizoaffective disorder.

Exploratory Aim: As an exploratory aim, the TMS test if TMS affects patterns of cigarette craving and if changes in cigarette craving are correlated to changes in functional connectivity. It is hypothesize that craving will decrease following iTBS administration. It is hypothesized that a decrease in cigarette craving will correlate with changes in brain network functional connectivity.

Psychotic disorders such as schizophrenia are disabling, lifelong illnesses that afflict over three million people in the US. The life expectancy of individuals with schizophrenia is ~25 years less than the general population. Tobacco use is the top preventable cause of early mortality in schizophrenia. The prevalence of smoking in schizophrenia is over 60%. It is unknown why nicotine dependence is so prevalent in schizophrenia, and nicotine dependence is not treated in schizophrenia differently than in the general population.

There is a significant gap in the understanding of nicotine dependence in psychotic disorders and how this diagnosis affects its treatment. Most neuroimaging studies of nicotine dependence are hypothesis-driven study designs focusing on reward circuitry. Studies of nicotine dependence in a psychotic population have typically used the same experimental design. This approach may be missing important circuits involved in nicotine dependence specific to psychotic disorders.

Her an agnostic, data-driven approach is used to investigate this problem. It is observed that individual variation in the severity of nicotine use is linked to individual variation in default mode network (DMN) organization.

Group 13, Grouped object Traditional imaging studies yield results which are correlational and do not test associations between findings. Therefore causality of nicotine-network interactions was tested. In an independent cohort, it was observed that acute nicotine administration reverses DMN hyperconnectivity in schizophrenia in a dose-dependent relationship. This is consistent with a model in which nicotine may correct schizophrenia-specific pathology.

The central hypothesis is this: Brain circuits most relevant to nicotine dependence in schizophrenia are distinct from pathways identified in a non-schizophrenia population. DMN disruption in schizophrenia is a well-replicated observation. Based on the data, it is hypothesized that individual variation in the magnitude of this network disruption gives rise to: a) variation in the severity of network disorganization and b) variation in severity of nicotine use. Further, it is proposed that the DMN mediates the relationship between nicotine use and cognition in schizophrenia. DMN hyperconnectivity is linked to poor attentional performance and, in healthy controls, nicotine can both reduce DMN connectivity and improve attention. It is proposed that DMN connectivity mediates the relationship between nicotine use and attentional performance and that disruption of this network in schizophrenia drives the need for nicotine to correct network pathology (and cognition). This model can be empirically tested: If the effect of nicotine on cognition is truly mediated by these networks, then 1) modulation of network connectivity should affect attentional performance and 2) the degree of network modulation should explain performance change irrespective of the method used to manipulate network connectivity.

To test the reproducibility of the results, multiple cohorts of participants with validated measures of nicotine dependence will be analyzed, clinical characterization, and brain imaging. To test the rigor of the scientific model, it is determined that if modulating these networks using a different (non-nicotine) intervention (Transcranial Magnetic Stimulation, TMS) can replicate nicotine's effects on cognitive performance.

In this study, transcranial magnetic stimulation (TMS) neuromodulation was used to target previously identified network pathophysiology unique to nicotine dependence in psychotic disorders. Here, a model is tested that integrates brain network pathophysiology and cognition to 1) explain the prevalence of nicotine use in schizophrenia and 2) identify a target for engagement in future clinical trials in schizophrenia and schizoaffective disorder.

  1. Functional connectivity as a measure of neural function

The human brain has evolved to perform different behaviors under different sets of conditions and as such must flexibly combine the functional processing capabilities of disparate neuroanatomical regions. Collections of structurally interconnected brain areas must interact dynamically to process a large and ever-changing set of inputs in the ultimate attempt to generate an appropriate behavioral output. Functional networks can therefore be defined as the collection of interconnected brain areas that interact to perform these circumscribed functions.

To identify the critical nodes involved in these different functional networks, much of the work in the field of functional neuroimaging has used the fMRI blood-oxygen-level-dependent (BOLD) signal as a marker of cerebral perfusion, which in turn is known to reflect cerebral activity. fMRI BOLD activation patterns have revealed network nodes that are involved in such cognitive functions as attention, working memory, language, and others.

In the resting state--while a subject is asked simply to look straight without performing a specific task in the MRI- analyses of the time-course of BOLD activation have revealed that activity patterns of several of these cerebral nodes exhibit coordinated fluctuations. As such, the activity patterns between particular nodes appear to be highly correlated in time while others seem relatively independent of one another. Taken together, these coordinated nodes can be thought of as a coupled functional network.

Interestingly, the degree to which these nodes appear correlated depends on task demands. In certain conditions, nodes will be highly correlated while, in others, these very same nodes appear rather independent. This degree of functional coupling within and between nodes of specific functional networks is therefore thought to reflect a change in distributed processing that is essential in mediating a change in cognitive functioning.

In the domain of attention in particular, several groups have shown a correlation between the strength of connectivity in specific networks and performance on tests that rely on this specific domain. Examples include functional connectivity analyses in healthy controls attention deficit hyperactivity disorder, neglect, and Parkinson's disease. Studies such as these have reliably demonstrated a correlation between measures of attention and the connectivity patterns of several key networks including the default mode network, the salience network (SN), the dorsal attention network (DAN) and the ventral attention network (VAN).

Using this paradigm, complex cognitive functions such as attention can now be understood and investigated by monitoring the dynamic coupling and uncoupling of nodes within these pre-defined networks.

  1. TMS effects on behavior and attention

TMS, (Transcranial Magnetic Stimulation) is a non-invasive, easily transportable, and relatively inexpensive procedure that utilizes magnetic fields to create electric currents in discrete brain regions. TMS is based on Faraday's principle of electromagnetic induction and features application of rapidly changing magnetic field pulses to the scalp via a copper wire coil connected to a magnetic stimulator. These brief pulsed magnetic fields painlessly pass through the skull and create electric currents in discrete brain regions of sufficient magnitude to depolarize neurons. Applied in single pulses (single-pulse TMS) appropriately delivered in time and space, the currents induced in the brain can be of sufficient magnitude to depolarize a population of neurons. When applied to the motor cortex, this depolarization results in a series of descending (direct and indirect) corticospinal waves that can sum-up at the spinal segmental level, depolarize alpha motor neurons and lead to the contraction of contralateral muscles. This can be measured, for example, as motor evoked potentials (MEPs) using electromyography (EMG). Applied to any cortical region, TMS evokes a local field potential that can be recorded with EEG, or other brain imaging techniques, and reveals a measure of cortical reactivity to TMS. TMS intensity can be parametrically varied in its intensity thus allowing the establishment of a dose-response curve and providing insights into cortical excitability.

Trains of repeated TMS pulses (rTMS) at various stimulation frequencies and patterns can induce a lasting modification of activity in the targeted brain region which can outlast the effects of the stimulation itself. Such lasting changes presumably represent alterations in plasticity mechanisms.

Therefore, TMS can be used with multiple pulses to facilitate activity in a region of the brain or suppress activity in a region of the brain. In this study,a specific form of rTMS called theta burst stimulation (TBS) is used.

This study seeks to provide evidence that targeted stimulation of a brain network leads to both altered network activity and a concomitant functional change in attention in individuals with schizophrenia and schizoaffective disorder. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of nicotine use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at improving attention and nicotine use in individuals with schizophrenia and schizoaffective disorder.

Being tested
iTBS to the DMN, cTBS to the DMN, Sham rTMS
Keywords
iTBS, cTBS, Schizophrenia, nicotine, sham, TMS
Medical subject headings
Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • iTBS to the DMNDevice

    Intermittent theta-burst frequency rTMS (iTBS) targeted to the parietal node of the default mode network.

  • cTBS to the DMNDevice

    Continuous theta-burst frequency rTMS (cTBS) targeted to the parietal node of the default mode network

  • Sham rTMSDevice

    Sham rTMS: coil flipped 180 degrees and applied to the parietal node of the DMN using an iTBS sequence. For this sham condition, rTMS felt and sounded like active stimulation, but no actual stimulation was delivered.

Study groups in NCT07190352
Study groupRoleWhat they receive
Nicotine Users with SchizophreniaExperimentalSubjects must report that they have been given a diagnosis of schizophrenia or schizoaffective disorder by a mental health professional and be a current nicotine user.
Receives: Device: iTBS to the DMN; Device: cTBS to the DMN; Device: Sham rTMS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Nicotine Craving

    Nicotine craving is assessed using 0-10 Visual Analog Scale (VAS) immediately before and after rTMS application. The VAS ranges from 0 to 10, where 0 indicates "no craving," and higher numbers indicate more craving.

    Measured: Immediately prior to and following rTMS.

Secondary outcomes (1)
  1. Resting State Functional Connectivity

    Functional connectivity of the entire default mode network (DMN) will be measured via resting-state fMRI collected immediately before and after rTMS. Whole network connectivity will be calculated by extracting the BOLD signal from from 7 standard nodes of the DMN (Raichle 2011), placing 6mm spheres at these coordinates, and calculating the average resting-state functional connectivity between all nodes. Higher values indicate smore strongly correlated BOLD signals in the nodes of the DMN.

    Measured: Immediately prior to and following rTMS.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Sep 2025
  2. Study start4 Oct 2021
  3. Primary completion3 Oct 2022
  4. Study completion3 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Crossover
Model description
Randomized, crossover study comparing a single session of iTBS, cTBS, and sham all targeted to the DMN in people with schizophrenia who use nicotine.
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07190352
Sponsor's protocol ID
2021P000749
Status last verified
Jul 2026
First submitted
2 Sep 2025
Last updated
30 Jul 2026
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No: Reasonable requests for data sharing will be considered.

Questions about this trial

What is this clinical trial studying?

A study testing iTBS to the DMN and cTBS to the DMN in people with SCHIZOPHRENIA 1 (Disorder) and Nicotine Use, run by Beth Israel Deaconess Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Nicotine Craving (time frame: Immediately prior to and following rTMS.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in